Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters

US healthcare stocks have significantly underperformed the broader market, slumping 5% in 2025 against the S&P 500's 7% gain, primarily due to Trump administration policies, regulatory hurdles, and sustained ETF outflows totaling $11.5 billion. This prolonged weakness has driven the sector to its largest discount relative to the broader market in 30 years, with attractive valuations like a forward P/E of 16.2x compared to the S&P 500's 22x. Consequently, some investors are now viewing the sector as a deep value opportunity, betting on a rebound and potential outperformance amid a tech rotation or economic slowdown, while others remain cautious about potential 'value traps'.

Analysis

The U.S. healthcare sector is experiencing significant underperformance, having declined 5% in 2025 in stark contrast to the S&P 500's 7% gain. This divergence is attributed to a persistent political and regulatory overhang, including Trump administration policies aimed at reducing drug prices, imposing tariffs, and cutting research funding. Investor sentiment has soured, evidenced by 12 consecutive months of net outflows totaling $11.5 billion from healthcare ETFs, the most of any sector. This prolonged weakness has driven the sector to its largest valuation discount relative to the broader market in 30 years, with its forward price-to-earnings ratio at 16.2x versus the S&P 500's 22x. Specific large-cap pharmaceuticals exhibit even deeper discounts, such as Merck (MRK) and Bristol Myers Squibb (BMY), which trade at approximately half of their long-term average P/E ratios. Consequently, a dichotomy has emerged: while some investors fear these stocks are 'value traps' with unclear catalysts, others are beginning to view the sector as a compelling deep-value opportunity, betting that the negative news is fully priced in and that a rebound could be triggered by capital rotation from tech or a flight to defensive assets amid signs of an economic slowdown.

Key Decisions for Investors

• Value-oriented investors should consider the historically low valuations in the healthcare sector, particularly in names like Merck (MRK) and Bristol Myers (BMY), which are trading at significant discounts to their long-term averages.
• Investors should closely monitor political and regulatory developments, as any clarification or easing of pressures on drug pricing and tariffs could serve as a major positive catalyst for the entire sector.
• Given its defensive characteristics and potential for a capital rotation from overvalued tech stocks, a tactical allocation to healthcare may be prudent for portfolios seeking to hedge against a potential economic downturn or market pullback.
• Monitor fund flows in healthcare ETFs for a reversal from the current $11.5 billion outflow trend, as a shift to net inflows would provide a strong technical signal that broader market sentiment towards the sector is improving.